Intravenous Flurbiprofen Axetil Enhances Analgesic Effect of Opioids in Patients with Refractory Cancer Pain by Increasing Plasma β-Endorphin

Wu, Tingting; Wang, Zhigang; Ou, Weihua; Wang, Jun; Yao, Guo-Qing; Yang, Bo; Rao, Zhiguo; Gao, Jian‐Fei; Zhang, Bicheng

doi:10.7314/apjcp.2014.15.24.10855

Cited by 7 publications

(8 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the combination CDDP and flurbiprofen needs careful consideration. Flurbiprofen axetil, flurbiprofen's prodrug, is used in cancer pain in clinical settings (Wu et al, 2014). Thus, patients administered CDDP may switch from flurbiprofen axetil to celecoxib, or alternative medications such as acetaminophen and tramadol, and a detailed clinical evaluation needs to be undertaken.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of the nephroprotective effects of non-steroidal anti-inflammatory drugs on cisplatin-induced nephrotoxicity in vitro and in vivo

Okamoto

Saito

Narumi

et al. 2020

European Journal of Pharmacology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

“…We considered that the difference between the in vitro and in vivo mechanisms might be associated with the NSAID activated gene 1 (NAG-1). NAG-1 is induced by NSAIDs, regardless of COX activity, and is related to apoptosis (Zhang et al, 2014). Furthermore, it has been suggested that celecoxib increases NAG-1 (Vaish et al, 2013).…”

Section: Discussionmentioning

confidence: 99%

Comparison of the nephroprotective effects of non-steroidal anti-inflammatory drugs on cisplatin-induced nephrotoxicity in vitro and in vivo

Okamoto

Saito

Narumi

et al. 2020

European Journal of Pharmacology

View full text Add to dashboard Cite

“…Sufficient postoperative pain control is essential to surgical outcomes and postoperative recovery [ 30 ]. Dezocine and flurbiprofen axetil, representatives of opioids and NSAIDs, respectively, are important components of perioperative pain management [ 20 , 31 , 32 ], and the combined application of the two differentially acting drugs is becoming widely accepted. Our center generally adopted a combination of PCIA sufentanil with intravenous flurbiprofen or parecoxib sodium.…”

Section: Discussionmentioning

confidence: 99%

“…Flurbiprofen axetil is one of the NSAIDs applied in this clinical setting as well [ 19 ]. As Wu et al demonstrated in patients with cancer, opioids incorporating with flurbiprofen axetil yielded better pain relief and reducing drug consumption in comparison to opioids alone [ 20 ]. Flurbiprofen axetil and dezocine have different analgesia mechanisms.…”

Section: Introductionmentioning

confidence: 99%

Effect of patient-controlled intravenous analgesia combined with flurbiprofen axetil and dezocine on postoperative analgesia for lobectomy (EPIC-FAD): a trial protocol

Zhou

Lin

et al. 2021

Trials

View full text Add to dashboard Cite

Background The optimal analgesic strategy for surgical pain after lobectomy remains undefined. To compare the combination of flurbiprofen axetil and dezocine with flurbiprofen axetil alone and dezocine alone, in post-lobectomy patients. Methods A single-center, parallel-design double-blind superiority trial, with 5 groups (1:1:1:1:1 ratio) with different combinations of flurbiprofen and dezocine. Patients scheduled for lobectomy will be recruited. The primary outcome is total sufentanil use in patient-controlled intravenous analgesia within the first 24 postoperative hours. Secondary outcomes include pain numeric rating scales at 6th, 12th, 24th, 48th, and 72th postoperative hours, and on the 1st, 3rd, and 6th postoperative months at rest and during coughing, adverse effects from experimental drug treatment, sufentanil use at other time points, analgesia cost, time to chest tube removal, length of hospital stay, time to pass first flatus, and serum level of cytokines. Doctors, patients, and nurses are blinded, and only the manager is unblinded. Analysis is intention-to-treat. Statistical analysis is pre-specified. Statistical comparison of the treatment groups includes one-way analysis of variance followed by Tukey’s post hoc test. Discussion Trial did not begin to recruit. Participant recruitment start date is planned to be June 1, 2020. Approximate recruitment end date is May 31, 2021. If successful, the trial may shed light on the use of certain analgesic combinations in post-lobectomy pain control. Trial registration Chinese Clinical Trial Registry ChiCTR1800018563. Registered on September 25, 2018.

show abstract

“…Flurbiprofen axetil is a non-selective and non-steroidal drug as an analgesic ( 14 ) that can achieve a targeting effect ( 15 ). Flurbiprofen axetil can be accumulated at the sites of injury and inflammation to inhibit the activity of cyclooxygenase (COX), which in turn achieves analgesic effect ( 16 ). In addition, flurbiprofen axetil can be absorbed by Mφ and Neu and other periglomerular (PG) cells to inhibit the synthesis and release of PG, thereby reducing tissue edema and inflammatory response caused by surgical trauma ( 17 , 18 ).…”

Section: Discussionmentioning

confidence: 99%

Effects of flurbiprofen on serum level of interleukin-6, prostacyclin and corticosteroid A2 in patients with bone metastases of cancer

Yin

et al. 2017

Oncol Lett

View full text Add to dashboard Cite

The present study aimed to investigate the effects of flurbiprofen on serum level of interleukin-6 (IL-6), prostacyclin (PGI2) and corticosteroid A2 (TXA2) in patients with bone metastases of cancer. A total of 210 patients with bone metastasis of cancer were randomly divided into two groups: Flurbiprofen axetil analgesia group (group A) and dezocine analgesia group (group B), 105 cases in each group. The analgesic effect was evaluated using visual analogue scale (VAS) scoring system at 1, 12, 24 and 48 h after treatment. Serum levels of IL-6, PGI2 and TXA2 at 12 and 24 h after treatment were detected using double-antibody sandwich enzyme-linked immunosorbent assay. No significant differences in VAS scores were found between the two groups at 1, 12, 24 and 48 h after treatment, and no gastrointestinal adverse events and abnormal bleeding were observed. No significant differences in the serum levels of IL-6 were found between the two groups at 12 and 24 h after treatment. Significantly lower serum levels of TXA2 and PGI2 were found in group A compared to group B at 12 and 24 h after treatment (P<0.05). Serum level of PGI2 was positively correlated with serum level of TXA2 (r=0.7212, P<0.05) and VAS score (r=0.7159, P<0.05). Serum level of IL-6 was positively correlated with VAS score (r=0.7997, P<0.05). The results show that flurbiprofen axetil can effectively relieve pain in patients with bone metastases of cancer, can inhibit platelet activation, adhesion and aggregation, and reduce the formation of deep vein thrombosis, and can inhibit stress response and inflammatory response in the body.

show abstract

Intravenous Flurbiprofen Axetil Enhances Analgesic Effect of Opioids in Patients with Refractory Cancer Pain by Increasing Plasma β-Endorphin

Cited by 7 publications

References 32 publications

Comparison of the nephroprotective effects of non-steroidal anti-inflammatory drugs on cisplatin-induced nephrotoxicity in vitro and in vivo

Comparison of the nephroprotective effects of non-steroidal anti-inflammatory drugs on cisplatin-induced nephrotoxicity in vitro and in vivo

Effect of patient-controlled intravenous analgesia combined with flurbiprofen axetil and dezocine on postoperative analgesia for lobectomy (EPIC-FAD): a trial protocol

Effects of flurbiprofen on serum level of interleukin-6, prostacyclin and corticosteroid A2 in patients with bone metastases of cancer

Contact Info

Product

Resources

About